ESMO 2018 Newsroom

 

Expert Opinions: Video Interviews

Looking Beyond Second-Line Treatment in mCRC
Interview with Prof. Dr Dirk Arnold
Watch the video interview here >>>

Sequencing in EGFR+ NSCLC
Interview with Dr Maximilian Hochmair
Watch the video interview here >>>

NSCLC: What Can EGFR TKI Sequencing Achieve?
Interview with Prof. Dr Thomas Wehler
Watch the video interview here >>>

Treatment Options in Second-Line NSCLC
Interview with PD Dr Alessandra Curioni
Watch the video interview here >>>

Biomarker-Guided Patient Selection for Targeted Therapies
Interview with Prof. Dr
Rodrigo Dienstmann

Watch the video interview here >>>

Personal Highlights in Breast Cancer
Interview with Dr Matteo Lambertini

Watch the video interview here >>>

Ovarian Cancer/Colon Cancer:
Personal Highlights
Interview with Dr Stefan Zimmermann
Watch the video interview here >>>

Practice-Changing Trials in
Breast Cancer
Interview with Dr Carmen Criscitiello
Watch the video interview here >>>

 

Poster Presentation: Neutropenia in mCRC
Interview with Alexander Meisel
Watch the poster presentation here >>>

 

 

 

Expert Opinions: Personal Highlights 
Personal Highlights from Dr Sara De Dosso
on gastrointestinal and neuroendocrine tumors
Read more
Personal Highlights from PD Dr Richard Cathomas
on genitourinary tumors
Read more

 

 

Article
  Metastatic Colorectal Carcinoma
Treatment After Second Disease Progression
The introduction of more lines of therapy in patients with metastatic colorectal carcinoma (mCRC) was one of the most important factors in prolonging overall survival (OS) in recent years. New therapeutic options such as trifluridine/tipiracil (TAS-102) or regorafenib have challenged the more traditional approaches for third and later lines of therapy, including rechallenge or reintroduction therapy. At a satellite symposium, Prof. Arnold discussed the different treatment options currently available after second disease progression.
Read more
Reference: Arnold D. Looking beyond second-line treatment in mCRC. Oral presentation presented at: ESMO 2018 Congress; 19–23 October; Munich, Germany.

 

Study Highlights

 

  Triple-Negative Breast Cancer
IMpassion130: Targeted treatment improves overall survival
For the first time, targeted immunotherapy has been shown to improve overall survival in triple-negative breast cancer. In the phase III IMpassion130 trial, patients were randomized 1:1 to atezolizumab plus nab-paclitaxel (n=451; median age: 55 years) or placebo plus nab-paclitaxel (n=451; median age: 56 years).
Read more
Reference: Schmid et al. 2018. IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). Oral presentation LBA1_PR presented at: ESMO 2018 Congress; 19–23 October; Munich, Germany.

 

Refractory Metastatic Gastric Cancer
TAS-102 prolongs OS and PFS
Patients with metastatic gastric or gastroesophageal junction cancer were randomized in TAGS 2:1 to either 35mg/m2 TAS-102 or placebo. Therapy was administered twice daily on days 1–5 and 8–12 of each 28-day cycle.
Read more
Reference: Arkenau et al. 2018. TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Oral presentation LBA25 presented at: ESMO 2018 Congress; 19–23 October; Munich, Germany.

 

  Non-Small-Cell Lung Cancer
Durvalumab versus standard of care in ≥3rd line NSCLC
The randomized phase III ARCTIC trial consists of two parts. In part A, non-small-cell lung cancer (NSCLC) patients with ≥25% programmed death ligand-1 (PD-L1) expression were randomized 1:1 to durvalumab or standard of care, which consisted of either erlotinib, gemcitabine or vinorelbine.
Read more
Reference: Kowalski et al. 2018. ARCTIC: durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥3L advanced NSCLC treatment. Oral presentation 1378O presented at: ESMO 2018 Congress; 19–23 October; Munich, Germany.

 

  HR+, HER2- Breast Cancer
PALOMA-3: Previously treated patients benefit from palbociclib plus fulvestrant
In the phase III PALOMA-3 study, patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer were randomized 2:1 to receive 125 mg palbociclib daily (3 weeks on, 1 week off) plus 500 mg fulvestrant every for weeks (q4w) (n=347) or placebo plus 500 mg fulvestrant q2w (n=174).
Read more
Reference: Cistrofanilli et al. 2018. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Oral presentation LBA2_PR presented at: ESMO 2018 Congress; 19–23 October; Munich, Germany.

 

  Head and Neck Squamous Cell Carcinoma
Pembrolizumab plus chemotherapy: The new standard of care in recurrent or metastatic head and neck squamous cell carcinoma?
At ESMO 2018, the comparison of pembrolizumab versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy from KEYNOTE-048 in patients with recurrent or metastatic head and neck squamous cell carcinoma was presented.
Read more
Reference: Burtness et al. 2018. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Oral presentation LBA8_PR presented at: ESMO 2018 Congress; 19–23 October; Munich, Germany.

 

  PIK3CA-mutant, HR+, HER2- Breast Cancer
Alpelisib plus fulvestrant shows significantly improved locally assessed PFS
In the phase III SOLAR-1 study, 572 patients with hormone-receptor (HR+), human epidermal growth factor receptor 2-negataive (HER2-) advanced breast cancer were randomized 1:1 to receive either 300 mg alpelisib plus 500 mg fulvestrant or placebo plus 500 mg fulvestrant.
Read more
Reference: André et al. 2018. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABD): results of the Phase 3 SOLAR-1 trial. Oral presentation LBA3_PR presented at: ESMO 2018 Congress; 19–23 October; Munich, Germany.

 

  Advanced Ovarian Cancer
Maintenance olaparib substantially improves PFS
In the randomized phase III SOLO1 trial, newly diagnosed patients with BRCA1/2-mutated advanced ovarian cancer received maintenance olaparib (300 mg twice daily; n=260) or placebo (n=131) until disease progression.
Read more
Reference: Gupta et al. Long-term mortality after the blood pressure and lipid-lowering treatment in hypertensive patients: 16-year follow-up of the ASCOT Legacy study. Oral presentation 1327 presented at: ESC 2018; 25–29 August; Munich, Germany.

 

  Oropharyngeal Cancer
Cisplatin plus radiotherapy remains standard of care in HPV+ oropharyngeal cancer
In DE_ESCALTE HPV Trial, patients with low-risk human papillomavirus-positive (HPV+) oropharyngeal cancer received 70Gy radiotherapy over 7 weeks. In addition, patients were randomized 1:1 to receive either cetuximab (400 mg pre-treatment, 250 mg thereafter; n=168)) or cisplatin (100mg/m2 at days 1, 22 and 43; n=166).
Read more
Reference: Mehanna et al. 2018. Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy. Oral presentation LBA9_PR presented at: ESMO 2018 Congress; 19–23 October; Munich, Germany.